- Open Access
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Biomarker Research volume 10, Article number: 90 (2022)
Correction: Biomark Res 10, 89 (2022)
The original article  contains an error in the following sentence:
‘When combining IMQ, photodynamic therapy (PDT) had a better effect on cutaneous squamous cell carcinoma (cSCC) than either IMQ or PDT alone.’
The mention of IMQ is erroneous and should instead be IMA (imatinib mesylate).
Sun H, et al. Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives. Biomark Res. 2022;10:89. https://doi.org/10.1186/s40364-022-00436-7.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Sun, H., Li, Y., Zhang, P. et al. Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives. Biomark Res 10, 90 (2022). https://doi.org/10.1186/s40364-022-00445-6